Charlie was recruited to BioGenerator in July of 2009. At the time of his recruitment, Charlie held the position of Principal Scientist and Project Leader in the Pfizer Exploratory Immunobiology group, where he led a reverse pharmacology project focusing on post-transcriptional regulation of T cell cytokines and was the Research Project Leader for small molecule discovery program targeting an effector T cell subtype-selective receptor. Prior to his work in immunology, Charlie led a Pfizer project targeting a mitochondrial protein involved in diabetes, and worked on biomarkers and pharmacology for several nuclear receptor projects. Before Pfizer, Charlie worked on pharma project teams in various therapeutic areas at Pharmacia and Searle, as well as in technology and screening groups. Charlie began his career in agricultural research at Monsanto, mainly in the area of genomics.
Charlie manages investments in pharma and agtech, as well as in adjacent industries. Example BioGenerator portfolio companies for Charlie include Wugen, Indalo Therapeutics, Adarza BioSystems, Arch Oncology, Medibeacon, SentiAR, Unleash IO, and CoverCress. Recent exits include Confluence Life Sciences, Array Bridge, and Synerz Medical. Charlie co-founded, and managed investments in BioGenerator portfolio company Canopy Biosciences, a rapidly growing research tools company, and Cadre Bioscience, a BioGenerator portfolio company developing novel therapeutics. Charlie also conceived of Elevant, a seed stage BioGenerator portfolio company focused on healthy living.
Charlie is a Co-Founder and Managing Director of Synchrony Bio, an early stage fund focused on active investing in diagnostics and medical devices.
In 2009, Joseph Monahan, CSO of Confluence Discovery Technologies, and Charlie founded the BioGenerator Labs, one of the first co-working labs in the country. Working closely with the Cortex Innovation Community, Charlie expanded the Labs in the Cortex-1 building in 2013. Charlie worked with Cortex and Washington University to again expand the BioGenerator Labs model to serve as the pillar for the Crescent building at 4340 Duncan, and played a key role in the vision for the building and its overall design. The reimagined 4340 building opened in 2019 with the BioGenerator Labs as the heart of the building, Confluence Discovery Technologies occupying its entire fourth floor, and Arch Oncology taking up half of the third floor. In late 2018, Charlie teamed with the St. Louis Economic Development Partnership to expand the BioGenerator Labs model to the 39 North district, launching a pilot focused on the needs of agtech clients.
Charlie conceived of the BioGenerator Grants, Fundamentals, and Grants2Businiess programs. Together with the BioGenerator Labs, these programs have impacted hundreds of inventors and entrepreneurs outside of the BioGenerator investment portfolio. Charlie manages a team of Entrepreneurs in Residence and Venture Capital Fellows at BioGenerator, creating and building new companies.
Away from work, Charlie spends as much time as he can with his three active children and his college sweetheart. When he has time to himself, Charlie enjoys working with his hands and taking care of whatever the latest challenge is at his century home in Kirkwood, Mo, or at the family’s farm near Slater, Mo.